Federal government reserves 2000 packages of a drug against covid-19
The federal government has signed another contract for the reservation of a promising drug against Covid-19. Since then, this is already the third contract of this kind with the company Glaxosmithkline.
The Federal Office of Public Health (FOPH) has signed a contract for access to 2,000 additional packs of the monoclonal antibody sotrovimab, developed by Glaxosmithkline in partnership with Vir Biotechnology. The antibody was discovered by Ticino-based Humabs Biomed in Bellinzona. The contract amount is confidential, he said.
This is already the third contract with Glaxosmithkline to reserve its Covid-19 drug following two orders in 2021 for 3000 and 2000 packs, respectively.
Sotrovimab was granted a temporary marketing authorization by Swissmedic on Jan. 14, 2022, under the name "Xevudy." Clinical trials showed that Xevudy can protect infected at-risk individuals from severe covid disease progression. The wolle will cover the costs of the treatments in the outpatient setting as long as they are not yet reimbursed by mandatory health insurance.
Source: BAG
